Education
About Us
Working with TipRanks
Follow Us
OncoZenge AB (DE:8LY)
FRANKFURT:8LY
8LY Stock Chart & Stats
€0.57
-€0.02(-7.82%)
At close: 4:00 PM EST
€0.57
-€0.02(-7.82%)
Day’s Range― - ―
52-Week Range€0.27 - €0.67
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€7.19M
Enterprise Value€70.26M
Total Cash (Recent Filing)€11.59M
Total Debt (Recent Filing)€7.50M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Feb 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding12,647,174
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)4.41
Price to Sales (P/S)43924.69
P/FCF Ratio-5.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
8LY FAQ
What was OncoZenge AB’s price range in the past 12 months?
OncoZenge AB lowest stock price was €0.27 and its highest was €0.67 in the past 12 months.
What is OncoZenge AB’s market cap?
OncoZenge AB’s market cap is €7.19M.
When is OncoZenge AB’s upcoming earnings report date?
OncoZenge AB’s upcoming earnings report date is Feb 18, 2026 which is in 57 days.
How were OncoZenge AB’s earnings last quarter?
OncoZenge AB released its earnings results on Oct 30, 2025. The company reported -€0.019 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.019.
Is OncoZenge AB overvalued?
According to Wall Street analysts OncoZenge AB’s price is currently Overvalued.
Does OncoZenge AB pay dividends?
OncoZenge AB does not currently pay dividends.
What is OncoZenge AB’s EPS estimate?
OncoZenge AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoZenge AB have?
OncoZenge AB has 12,647,174 shares outstanding.
What happened to OncoZenge AB’s price movement after its last earnings report?
OncoZenge AB reported an EPS of -€0.019 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of OncoZenge AB?
Currently, no hedge funds are holding shares in DE:8LY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OncoZenge AB
OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The company was founded in 2020 and is headquartered in Bromma, Sweden. OncoZenge AB (publ) is a subsidiary of Moberg Pharma AB (publ).
Technical Analysis
LIDDS AB
―
Lipigon Pharmaceuticals AB
―
Modus Therapeutics Holding AB
―
ExpreS2ion Biotech Holding AB
―
Sprint Bioscience AB
―